$273,938.18 ownership Payment -- Novartis Pharmaceuticals to Dr. Matthew Walker
Ophthalmologist Matthew Walker Receives Significant Ownership Stake in Novartis Pharmaceuticals
This page provides a detailed analysis of a $273,938.18 ownership payment from Novartis Pharmaceuticals to Dr. Matthew Walker. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $273,938.18 |
| Payment Type | ownership |
| Payment Nature | Ownership or Investment Interest |
| Pharmaceutical Company | Novartis Pharmaceuticals |
| Physician | Dr. Matthew Walker |
| NPI Number | 1453412140 |
| Physician Specialty | Ophthalmology |
| Location | Trenton, NJ |
| Date of Payment | 2024-11-30 |
| Related Drug/Device | Skyrizi |
| Conflict Assessment | High -- Significant |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Novartis Pharmaceuticals made a $273.9K ownership payment to Matthew Walker, a Ophthalmology specialist in Trenton, NJ. The payment was associated with Skyrizi. Matthew Walker received a substantial ownership interest payment of $273,938.18 from Novartis Pharmaceuticals. This payment is categorized as an 'Ownership or Investment Interest', indicating a financial stake beyond direct compensation for services. The payment is associated with the drug 'Skyrizi', suggesting a potential link between the investment and the promotion or use of this specific pharmaceutical.
Patient Guidance: What This Payment Means for You
If you are a patient, understand that your doctor may have financial interests in pharmaceutical companies or their products, which is disclosed through programs like CMS Open Payments. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Ownership interest payments to physicians can vary widely depending on the specialty and the nature of the investment; this particular payment is substantial and may warrant closer examination within the context of ophthalmology.
Regulatory Context: Sunshine Act Requirements
This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug and device manufacturers and physicians.
Related Topics
This payment is related to the following healthcare transparency topics:
- ownership-interest
- pharmaceutical-investment
- ophthalmology
- novartis-pharmaceuticals
- skyrizi
- physician-payment
Understanding ownership Payments
Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.
Frequently Asked Questions About This Payment
What was this $273.9K payment for?
This was a ownership payment of $273.9K from Novartis Pharmaceuticals to Matthew Walker, categorized as "Ownership or Investment Interest". It was associated with Skyrizi. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Matthew Walker accept pharmaceutical money?
Yes, Matthew Walker received this $273.9K payment from Novartis Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Matthew Walker's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this ownership payment?
A ownership payment of $273.9K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Ophthalmology?
To compare this payment against Ophthalmology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Ophthalmology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Matthew Walker's relationship with Novartis Pharmaceuticals?
The payment amount is notably high for an ownership interest, warranting further investigation into the nature of the investment. This $273.9K ownership payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Ophthalmology?
The specific drug 'Skyrizi' is mentioned, which could imply a focus on ophthalmological treatments within Novartis's portfolio.
What should patients do after learning about this payment?
If you are a patient, understand that your doctor may have financial interests in pharmaceutical companies or their products, which is disclosed through programs like CMS Open Payments.
What else should I know about this ownership payment?
The payment date of November 30, 2024, is in the future, which is unusual for a reported payment and may indicate a data entry error or a planned future transaction.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.